Page 3 - Michael Benkowitz News Today

/PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2021. Total revenue in the...

Operator Good morning, and welcome to the United Therapeutics Corporation First Quarter 2021 Earnings Call. My name is Phyllis, and I will be your conference operator today. [Operator Instructions] I will now turn the conference call over to Mr. Dewey Steadman, Head of Investor Relations at the United Therapeutics. Dewey Steadman -- Head of Investor Relations Good morning. Its my pleasure to welcome you to the United Therapeutics Corporation First Quarter 2021 Earnings Call. Accompanying me on...

Message : Required fields SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 5, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2021. Total revenue in the first quarter of 2021 grew 6% year over year to $379.1 million, compared to $356.3 million in the first quarter of 2020. "2021 is already a historic year for United Therapeutics, with the recent FDA approval and launch of Tyvaso for treatment of...

United Therapeutics Corporation Reports First Quarter 2021 Financial Results Tyvaso® (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) Tyvaso DPI™ New Drug Application (NDA) submitted to U.S. Food and Drug Administration TETON study of Tyvaso in idiopathic pulmonary fibrosis (IPF) expected to enroll its first patients in the second quarter of 2021 News provided by Share this article Share this article SILVER SPRING, Md. ...

United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease First and only approved therapy in the United States for patients with PH-ILD, a serious, life-threatening disease with potentially more than 30,000 patients in need FDA approval based on data from the INCREASE clinical trial PH-ILD is the second FDA-approved indication for Tyvaso, which was initially approved for the treatment of pulmonary arte...

MedCity News United Therapeutics notches another FDA approval for lung drug The FDA decision for Tyvaso as a treatment for pulmonary arterial hypertension in patients who have interstitial lung disease is the second approval for the United Therapeutics drug. The additional indication gives the company another way to grow revenue for the drug, which faces generic competition. Shares0   United Therapeutics has received FDA approval for its drug, treprostinil, as a treatment for high blood pres...

Operator Good morning, and welcome to the United Therapeutics Corporation Fourth Quarter 2020 Earnings Call. My name is Kenzie, and I will be your conference operator today. [Operator Instructions] I will now turn the conference call over to Mr. Dewey Steadman, Head of Investor Relations at United Therapeutics. Dewey Steadman -- Head of Investor Relations Good morning. Its my pleasure to welcome you to the United Therapeutics Corporation Fourth Quarter 2020 Earnings Call. Accompanying me on to...

United Therapeutics Corporation To Present At The 41st Annual Cowen Health Care Conference News provided by Share this article Share this article SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the companys business during a fireside chat session at the 41st annual Cowen...

United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease INCREASE Study is First to Demonstrate a Clear Benefit in Patients with PH-ILD, a Life-threatening Disease with No Currently FDA-Approved Treatments Company to host a webcast detailing the INCREASE study results on Tuesday, January 19, 2021 at 4:30 p.m. E.T. News provided by Share this article Share this article S...

United Therapeutics Announces Agreement To Acquire Priority Review Voucher Voucher expected to be applied to the forthcoming NDA for Tyvaso DPI™ News provided by Share this article Share this article SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 28, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV), which it plans to use with a forthcoming New Drug Application (NDA) wi...